![Ryan Saadi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ryan Saadi
Keine laufenden Positionen mehr
Vermögen: 96 Mio $ am 31.05.2024
Aktive Positionen von Ryan Saadi
Unternehmen | Position | Beginn | Ende |
---|
Karriereverlauf von Ryan Saadi
Ehemalige bekannte Positionen von Ryan Saadi
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Vorstandsvorsitzender | 01.06.2020 | - |
Vorsitzender | 01.06.2020 | - | |
Gründer | 01.06.2020 | - |
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Chief Executive Officer | 2 |
Chairman | 2 |
Founder | 2 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Health Technology |
- Börse
- Insiders
- Ryan Saadi
- Erfahrung